Holdings of BlackRock Health Sciences Opportunities Portfolio
BlackRock Funds · Original filing · Compare with another fund · Report an error
- Net assets
- 6.5B $ including 6.4B $ in equities, 97.3 %
- Positions
- 140 in 14 countries
- Top ten
- 46.9 % of net assets
- Filed on
- Feb 27, 2026
Portfolio shape
Positions
| Rank | Company | Shares | Value | Weight |
|---|---|---|---|---|
| 101 | BridgeBio Oncology Therapeutics Inc | 673,766 | 6.8M $ | 0.10 % |
| 102 | Oruka Therapeutics Inc | 185,015 | 6.4M $ | 0.10 % |
| 103 | Immunome Inc | 288,792 | 6.3M $ | 0.10 % |
| 104 | Mettler-Toledo International Inc | 4,594 | 6.3M $ | 0.10 % |
| 105 | Olema Pharmaceuticals Inc | 253,931 | 6.1M $ | 0.09 % |
| 106 | Immunocore Holdings PLC | 188,691 | 6.1M $ | 0.09 % |
| 107 | Dianthus Therapeutics Inc | 108,033 | 6M $ | 0.09 % |
| 108 | Disc Medicine Inc | 86,558 | 5.8M $ | 0.09 % |
| 109 | Alcon AG | 65,553 | 5.7M $ | 0.09 % |
| 110 | PTC Therapeutics Inc | 82,970 | 5.7M $ | 0.09 % |
| 111 | Monte Rosa Therapeutics Inc | 318,162 | 5.6M $ | 0.09 % |
| 112 | Vaxcyte Inc | 87,540 | 5.4M $ | 0.08 % |
| 113 | Aktis Oncology Inc | 266,503 | 5.4M $ | 0.08 % |
| 114 | Kodiak Sciences Inc | 188,769 | 5.1M $ | 0.08 % |
| 115 | Kymera Therapeutics Inc | 54,173 | 4.9M $ | 0.08 % |
| 116 | WaVe Life Sciences Ltd | 345,882 | 4.8M $ | 0.07 % |
| 117 | Beam Therapeutics Inc | 168,010 | 4.8M $ | 0.07 % |
| 118 | BioNTech SE | 41,921 | 4.6M $ | 0.07 % |
| 119 | Dyne Therapeutics Inc | 278,934 | 4.4M $ | 0.07 % |
| 120 | Zealand Pharma A/S | 74,091 | 4.3M $ | 0.07 % |
| 121 | Biohaven Ltd | 348,832 | 4M $ | 0.06 % |
| 122 | CG oncology Inc | 59,514 | 3.5M $ | 0.05 % |
| 123 | KalVista Pharmaceuticals Inc | 212,587 | 3.5M $ | 0.05 % |
| 124 | Allogene Therapeutics Inc | 1,208,862 | 3.4M $ | 0.05 % |
| 125 | EyePoint Inc | 186,478 | 3.3M $ | 0.05 % |
| 126 | Upstream Bio Inc | 341,675 | 2.6M $ | 0.04 % |
| 127 | Ocular Therapeutix Inc | 258,781 | 2.3M $ | 0.04 % |
| 128 | Corvus Pharmaceuticals Inc | 110,424 | 2M $ | 0.03 % |
| 129 | REGENXBIO Inc | 214,663 | 1.9M $ | 0.03 % |
| 130 | Vor BioPharma Inc | 115,078 | 1.8M $ | 0.03 % |
| 131 | Voyager Therapeutics Inc | 371,161 | 1.5M $ | 0.02 % |
| 132 | Nyxoah SA | 337,359 | 1.4M $ | 0.02 % |
| 133 | Autolus Therapeutics PLC | 728,967 | 1.2M $ | 0.02 % |
| 134 | 4D Molecular Therapeutics Inc | 126,274 | 1.2M $ | 0.02 % |
| 135 | Orchestra BioMed Holdings Inc | 206,130 | 902.8K $ | 0.01 % |
| 136 | TScan Therapeutics Inc | 556,653 | 590.1K $ | 0.01 % |
| 137 | BLUEPRINT MEDICINES CORP | 204,909 | 204.9K $ | 0.00 % |
| 138 | MIRATI THERAPEUTICS INC | 228,510 | 180.5K $ | 0.00 % |
| 139 | Gossamer Bio Inc | 365,199 | 155.2K $ | 0.00 % |
| 140 | Atrium Therapeutics Inc | 9,948 | 146.7K $ | 0.00 % |
Sector breakdown
- Health care 81.8 %
- Technology 0.3 %
- Unattributed 17.9 %
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
- USD 97.5 %
- GBP 1.5 %
- CHF 0.5 %
- EUR 0.3 %
- JPY 0.2 %
- DKK 0.1 %
The quoted currency of each line, as declared.
Country breakdown
- United States 93.4 %
- Israel 1.9 %
- United Kingdom 1.5 %
- Netherlands 1.5 %
- Switzerland 0.5 %
- Belgium 0.3 %
- Bermuda 0.2 %
- Japan 0.2 %
- Canada 0.1 %
- Jersey 0.1 %
- Singapore 0.1 %
- Germany 0.1 %
- Other countries 0.1 %
Shares computed on the equity sleeve.
| Rank | Country | Lines | Value | Share |
|---|---|---|---|---|
| 1 | United States | 124 | 5.9B $ | 93.40 % |
| 2 | Israel | 1 | 117.7M $ | 1.85 % |
| 3 | United Kingdom | 2 | 95.9M $ | 1.51 % |
| 4 | Netherlands | 1 | 93.1M $ | 1.46 % |
| 5 | Switzerland | 2 | 34.7M $ | 0.55 % |
| 6 | Belgium | 2 | 17.5M $ | 0.27 % |
| 7 | Bermuda | 1 | 13.6M $ | 0.21 % |
| 8 | Japan | 1 | 13.3M $ | 0.21 % |
| 9 | Canada | 1 | 8M $ | 0.13 % |
| 10 | Jersey | 1 | 7.9M $ | 0.12 % |
| 11 | Singapore | 1 | 4.8M $ | 0.08 % |
| 12 | Germany | 1 | 4.6M $ | 0.07 % |
Cite this page
Titelia. "Holdings of BlackRock Health Sciences Opportunities Portfolio". https://titelia.com/en/funds/S000001877